Skip to main content
An official website of the United States government

erlotinib hydrochloride

View Patient Information
The hydrochloride salt of a quinazoline derivative with antineoplastic properties. Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
US brand name:Tarceva
Code name:CP-358
CP-358,774
OSI-774
Chemical structure:N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine monohydrochloride
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search